Moderna shares surged in pre-market trading after the US biotech announced that its personalised mRNA cancer vaccine, intismeran, showed a statistically significant reduction in melanoma recurrence in a late-stage clinical trial.
The news, released on Wednesday, sent Moderna's stock soaring by more than 100 per cent in early trading as investors reacted to what some analysts described as a potentially significant development in personalised cancer treatment.